Invest In A Potential Cure For Osteoarthritis
Now we're advancing toward the next phase of FDA clinical trials in a $560B market that has no cure.
- Phase 1 FDA human clinical trial completed, safety confirmed.
- Partnered with leading researchers at Stanford Uni and Scripps.
- Investing today at a $160M valuation, projected to reach $4B at Phase 2 completion.
Osteoarthritis Therapeutics Is a $560B+ Market With No Real Cure
500M+ people worldwide live with osteoarthritis. Every current treatment only masks the pain while the disease quietly progresses toward costly, invasive joint replacements. Big Pharma spent $1B+ chasing a cure and came up short, because they targeted a single enzyme with an oral drug rather than addressing the full complexity of the disease.
Cytonics took a different approach
Designed to attack osteoarthritis at its root cause, delivering potent protease inhibition and cartilage repair directly into the joint.
How CYT-108 Works
CYT-108 is a genetically engineered “super A2M” protein that is >200% more potent than the naturally-occurring A2M protein
A2M is a naturally-occurring protease inhibitor that protects against cartilage degradation, but levels are too low in joints to be an effective treatment.
CYT-108 is delivered in massive, supraphysiological concentrations (17x natural A2M levels in the joint) for extremely potent inhibition of proteases and stimulation of cartilage-secreting chondrocytes.
1
2
3
A2M: Leveraging Natures Beautiful Design
At the core of our technology is Alpha-2-macroglobulin (A2M) - a naturally occurring protein that acts as the body’s molecular defense system. It is found in the blood stream and plays a role in blood clotting through a mechanism called protease inhibition. Cartilage breakdown in arthritis is also caused by these destructive proteases. Cytonics hypothesized that A2M’s mechanism of action could be leveraged to inhibit the multitude of protease enzymes that drive cartilage breakdown in arthritic joints.
A2M is one of the most well-studied proteins in human biology. Its structure was crystallized in 2012, and more than 90,000 peer-reviewed studies support its role as abroad-spectrum protease inhibitor. Its two “bait regions” function like a molecular Venus Flytrap, binding and deactivating these destructive enzymes. A2M is such a potent protease destroyer that it has been dubbed the Physiological Guardian because of its ability to protect many different tissue types throughout the body.
“So, if the human body is already full of A2M in the bloodstream, then why doesn’t it just naturally protect joints from arthritic decay?”
Cytonics’ approach is simple: Leverage the therapeutic power of A2M by delivering high concentrations of this miraculous protein directly into arthritic joints to halt cartilage damage, reduce joint membrane inflammation, and stimulate cartilage regrowth.
.webp)
2026 Is a Critical Year for Cytonics
Today's financing values Cytonics at $160M, at the Phase 1 stage. Based on management's risk-adjusted valuation model, a successful path through FDA approval could represent a potential 273x return for investors who get in now.3
"These statements reflect management’s current views based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results. Please see Data Room for additional detail regarding the assumptions underlying these projections."
Strategically Partnered with Rener & Eve Gracie
A third-generation Brazilian Jiu-Jitsu master and former WWE champion, Rener and Eve Gracie’s investment in Cytonics carries real weight. As two of the world’s most respected figures in athletics, injury prevention, and health advocacy, they bring credibility, visibility, and real-world expertise.
Health & Performance Advocacy:
Real-World Alignment:
Brand Expansion & Awareness:
Exclusive Investor Perks
Stay connected with the latest developments at Cytonics
CYT-108 Beyond Arthritis
.webp)
Duke ARPA-H (Tissue Regeneration Story)
CEO Profile
Phase 1 Study Report Finalized.
Founder Profile.
%20(1).webp)
Intro Medical Advisory Board.
New Canadian Patent.
.webp)
Clinical Development Is Not Hope. It’s Design.
Phase 1 Study Report Drafted.
.webp)
We are scaling the biology
.webp)
We’re Live. Again. And We’re Not Slowing Down.
Led by Seasoned Scientists, Physicians, and Industry Outsiders
Our leadership combines world-class scientific expertise, decades of clinical experience, and a proven track record in biotech R&D with the first-principles thinking of biotech neophytes (our Founder and CEO). Our Board of Directors and Medical Advisory Board have dominated the last decade of osteoarthritis research (a combined 80 osteoarthritis clinical trials), developed FDA-approved biologics at major pharma companies, and raised millions in combined capital. This unique combination of traditional biotech experience with avant garde thinking of industry outsiders gives us a strategic advantage as we tackle a problem that the Big Pharma giants have failed to solve.
- Proven innovator in orthopedic medicine, with 45+ peer-reviewed publications
- Served as faculty at Stanford and brings 30+ years of surgical experience
- Deep patient insight, leveraging decades of frontline experience treating joint degeneration
- 5th degree black belt jiu jitsu
- 15+ years in biotechnology R&D with healthcare investment banking experience
- Led funding efforts to secure $25M in non-VC investor backing
- Proven track record in clinical trial execution, patent protection, and securing licensing opportunities
- Johns Hopkins trained biomedical engineer with specialization in recombinant protein engineering
- GMP and regulatory affairs veteran with deep experience in biologics and vaccine programs
- Trained microbiologist and immunologist
- Built and led quality systems and global inspection readiness efforts
- Supported INDs reviewed by FDA, EMA, MHRA, and NMPA
- Former BARDA and FDA Office of the Commissioner leader in medical countermeasures
- Leads GMP-compliant manufacturing of CYT-108 at Cytonics from day one
- Responsible for communicating Cytonics’ science, strategy, and long-term vision to investors and the public
- Specializes in translating complex biology into clear, disciplined narratives
- Extensive experience with early- and growth-stage companies in regulated, capital-intensive industries
- Oversees brand development, campaign strategy, and digital advertising supporting capital formation and investor education
- Focuses on precision-driven storytelling that maintains scientific and regulatory integrity
- Architect of FOCAL, the company’s osteoarthritis AI engine
- Applies AI-driven modeling to digitally optimize CYT-108 clinical trials for human success
- Brings 20+ years of experience in AI, cloud computing, data engineering, and security
- Former leader in national-security encryption, offensive security (NTT Com Security), and scaled DigitalOcean from 5,000 to 100,000+ customers
- Dedicated technologist focused on continuous learning across Kubernetes, AI inference, and network security
Frequently Asked Questions
Why invest in startups?
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
How much can I invest?
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
How do I calculate my net worth?
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Who can invest in a Regulation CF Offering?
Individuals over 18 years of age can invest.
What do I need to know about early-stage investing? Are these investments risky?
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
When will I get my investment back?
The Common Stock (the "Shares") of Cytonics (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Can I sell my shares?
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
Exceptions to limitations on selling shares during the one-year lockup period:
In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities;
• An accredited investor;
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships).
What happens if a company does not reach their funding target?
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
How can I learn more about a company's offering?
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
What if I change my mind about investing?
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
How do I keep up with how the company is doing?
At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
What relationship does the company have with DealMaker Securities?
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
What is Cytonics Corporation's pre-money implied valuation?
Cytonics Corporation's pre-money implied valuation is $146,730,116.00. The implied valuation was calculated by multiplying the total number of shares outstanding (TSO) by the price per share offered in this raise. This is a pre-money implied valuation — meaning it reflects the company's value before any new funds raised in this offering are added.